Moderna Inc. shares declined as the company’s cost-cutting efforts failed to assuage investors who are worried about the ...

MRNA tops Q2 estimates with a narrower loss and revenue beat, but the stock slips after trimming 2025 sales guidance.

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13)Updates 2025 projected revenue range to $1.5 to $2.2 billion, reflecting a $300 million ...